trending Market Intelligence /marketintelligence/en/news-insights/trending/6l13ysuw-xlmjqlalig32a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK to boost Shingrix production, expects shortage throughout 2019

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


GSK to boost Shingrix production, expects shortage throughout 2019

GlaxoSmithKline PLC spokesman Sean Clements said the company plans to significantly increase shipments of its shingles vaccine Shingrix to the U.S. amid "unprecedented" demand, FiercePharma reported.

Clements said that healthcare professionals have been vaccinating at a much higher rate than in previous years, so GSK expects ordering limits to persist through 2019 in order to ensure the vaccine is distributed "fairly and equitably."

GSK, which was forced to implement order limits and delay TV advertising due to the shortage, intends to expand its overall supply capacity to the "high teen millions" annually, the report noted.

Shingrix, which takes up to nine months to produce, received approval from the European Commission and the Japanese Ministry of Health, Labour and Welfare in March 2018, and from the U.S. Food and Drug Administration in October 2017. The vaccine was shown to be more effective than Merck & Co. Inc.'s Zostavax.

Shingles, or herpes zoster, is a painful rash that develops on one side of the face or body caused by the varicella-zoster virus, the same virus that causes chickenpox.